The grant will fund the development of a novel formulation of SNX631-6, the Company's CDK8/19 Mediator kinase inhibitor and clinical candidate as a treatment for metastatic ovarian cancer (OC).

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

Macrophages can be repolarised via inhibition of the phosphoinositide 3-kinase-gamma (PI3Kγ) pathway, but this has little impact on the growth of pancreatic cancer. Macrophage efferocytosis induces a ...

Tumor invasion and angiogenesis ... Our results indicate that EGCG, as direct inhibitor of MMPs, inhibits angiogenesis and metastasis upstream of the action of angiogenesis inhibitors derived ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

AI Innovation Unlocks Non-Surgical Way to Detect Brain Cancer Spread Jan. 14 ... with a clinically investigative glutamine metabolism inhibitor, CB-839, can overcome tumor resistance and ...

Patients with stage III MCC (nodal spread) have survival ... with high mutational loads. 5 PD-1 inhibitor therapies enhance the body’s immune response to cancer cells, improving clinical ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

Over-expression of PRSS3 promoted pancreatic cancer cell proliferation as well as invasion in vitro, and tumour progression and metastasis in vivo. Stepwise investigations demonstrated that PRSS3 ...